The tweet was deleted by the author.
But we saved everything 🙂.
Outlook Therapeutics has announced the pricing of a 5.0 million dollar registered direct offering that is priced at-the-market under Nasdaq rules.
The fundraising move aims to bolster the company’s capital position and support its ongoing operations. The offering is being conducted in accordance with Nasdaq at-the-market pricing regulations, which often reflect the current market value rather than a set discount. The capital raise and its execution strategy may affect the company’s liquidity profile and investment outlook. Further details regarding the use of proceeds and investor participation have not yet been disclosed.
Earlier, Outlook Therapeutics won an appeal following a formal dispute resolution process related to ONS-5010 LYTENAVA, advancing the product’s development progress. Details of the dispute resolution can be found in a previous report. The appeal outcome preceded the company’s current fundraising efforts.